Loading...
Treprostinil Dependence And Litigation Risks Will Undermine Long Term Pulmonary Hypertension Prospects
AN
AnalystLowTarget
Not Invested
Community Contributor
Published
22 Dec 25
Views
27
22 Dec
US$61.97
AnalystLowTarget's Fair Value
US$16.99
264.8% overvalued intrinsic discount1Y
298.3%7D
4.5%1Y
298.3%7D
4.5%You can edit this narrative until Dec 23 7:05 PM. Then, changes will post as Updates.
Author's Valuation
US$16.99264.8% overvalued intrinsic discount
AnalystLowTarget Fair Value